Zobrazeno 1 - 3
of 3
pro vyhledávání: '"van Tinteren, Harm"'
Autor:
Meulendijks, Didier, van Hasselt, J G Coen, Huitema, Alwin D R, van Tinteren, Harm, Deenen, Maarten J, Beijnen, Jos H, Cats, Annemieke, Schellens, Jan H M
BACKGROUND: The objective of this analysis was to determine the factors associated with early onset treatment-related toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. PATIENTS AND METHODS: A total of 14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______101::1bfed9376e1ed6c05f0de15f5672c26e
https://dspace.library.uu.nl/handle/1874/346170
https://dspace.library.uu.nl/handle/1874/346170
Publikováno v:
LANCET ONCOLOGY, 16(16), e582–e583. Lancet Publishing Group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=narcis______::fea81a1873978896aaf1676683b25a06
https://dspace.library.uu.nl/handle/1874/337787
https://dspace.library.uu.nl/handle/1874/337787
Autor:
Lam, Siu W., Nota, Nienke M., Jager, Agnes, Bos, Monique M E M, Van Den Bosch, Joan, Van Der Velden, Ankie M T, Portielje, Johanneke E A, Honkoop, Aafke H., Van Tinteren, Harm, Boven, Epie, De Groot, S. M., Linn, S. C., Braun, H. J., Los, M., Kroep, J. R., Tanis, B., Smorenburg, C. H., Terwogt, J. M Meerum, Van Riel, J. M G H, Den Boer, M. O., Douma, J., Jeurissen, F., Berends, J.
Publikováno v:
Lam, S W, Nota, N M, Jager, A, Bos, M M E M, van den Bosch, J, van der Velden, A M T, Portielje, J E A, Honkoop, A H, van Tinteren, H & Boven, E 2016, ' Angiogenesis-and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy ', Clinical Cancer Research, vol. 22, no. 7, pp. 1611-1620 . https://doi.org/10.1158/1078-0432.CCR-15-1005
Clinical Cancer Research, 22(7), 1611-1620. American Association for Cancer Research Inc.
Clinical Cancer Research, 22(7), 1611. American Association for Cancer Research Inc.
Clinical Cancer Research, 22(7), 1611-1620. American Association for Cancer Research Inc.
Clinical Cancer Research, 22(7), 1611. American Association for Cancer Research Inc.
Purpose: We examined whether pretreatment levels of angiogenesis- or hypoxia-related proteins and their changes after one cycle of first-line bevacizumab-based therapy were associated with response, PFS, or OS in patients with metastatic breast cance